Brian Powl

Brian Powl joined Kura as Chief Commercial Officer in August 2023, with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products. Most recently, he served as Chief Commercial Officer for Fate Therapeutics, where he led the commercialization efforts for the company’s oncology and immunology portfolio. Previously, Mr. Powl was Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies. Earlier in his career, Mr. Powl held positions of increasing responsibility at Celgene Corporation including Vice President, Global Commercial CAR T lead, where he led the commercialization efforts of ABECMA^® and BREYANZI^® and served as the Global Marketing lead for Celgene’s flagship multiple myeloma franchise during the life cycle expansion of REVLIMID^® and POMALYST^®. Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.